KCM
XFOR icon

Kennedy Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Kennedy Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,795
Closed -$199K – 636
2022
Q1 		$199K Sell
3,795
-588
-13% -$33.7K ﹤0.01% 591
2021
Q4 		$301K Buy
+4,383
New +$554K 0.01% 589

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Kennedy Capital Management's XFOR Position: Q2 2022 in Review

Kennedy Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2022, closing a stake of 3,795 shares — an estimated $199K sold.

Kennedy Capital Management first reported a position in XFOR in Q4 2021 and held it in 2 quarters. The position peaked at $301K in Q4 2021. 49 funds tracked by Wall St. Rank hold XFOR as of Q2 2022.

  • Kennedy Capital Management reported no remaining X4 Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Kennedy Capital Management sold 3,795 X4 Pharmaceuticals shares in Q2 2022, an estimated $199K.
  • Kennedy Capital Management first reported a position in X4 Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Kennedy Capital Management's X4 Pharmaceuticals position peaked at $301K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2022.

Based on Kennedy Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.